Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms

We explored variables associated with patient-reported outcomes (PROs) including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and health-related quality of life in 1500 respondents with myeloproliferative neoplasms (MPNs) including essenti...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2021-09, Vol.62 (11), p.2703-2715
Main Authors: Shi, Dayu, Shi, Hongxia, Liu, Xiaoli, Duan, Minghui, Zhuang, Junling, Du, Xin, Qin, Ling, Hui, Wuhan, Liang, Rong, Wang, Meifang, Chen, Ye, Li, Dongyun, Yang, Wei, Tang, Gusheng, Zhang, Weihua, Kuang, Xia, Su, Wei, Han, Yanqiu, Chen, Limei, Xu, Jihong, Liu, Zhuogang, Huang, Jian, Zhao, Chunting, Tong, Hongyan, Hu, Jianda, Chen, Chunyan, Chen, Xiequn, Xiao, Zhijian, Jiang, Qian
Format: Article
Language:English
Subjects:
CALR mutation
MPN-10
Myeloproliferative neoplasm
patient-reported outcome
ruxolitinib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We explored variables associated with patient-reported outcomes (PROs) including symptom burden, impact on daily life and work, obstacles during therapy, satisfaction level with therapy, and health-related quality of life in 1500 respondents with myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) in a multicenter, cross-sectional study across China, a representative of the developing countries. In multivariate analyses, urban household registration and higher education level were significantly-associated with no symptoms at diagnosis in respondents with ET or MF. CALR mutation was significantly-associated with lower MPN-10 scores in respondents with MF. Higher MPN-10 scores were significantly-associated with negative impact on daily life and work as well as lower satisfaction level in respondents with ET, PV and MF. Receiving ruxolitinib was significantly-associated with high satisfaction and satisfaction in respondents with MF. In addition, other demographics and clinical variables were also impacting PROs.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428194.2021.1933481